First author Kaline Arnauts (Catholic University of Leuven, Belgium) explained the hypothesis that in order to study UC in an ex vivo model, inflammation should be re-induced towards levels corresponding to the in vivo situation. The researchers also wanted to know if organoids derived from inflamed regions are relatively sensitive to inflammatory stimulation. They therefore obtained biopsies from 8 patients with active UC, both from inflamed and non-inflamed regions, and from 8 non-IBD controls.
Exposure to the inflammatory mix induced transcriptional activation of inflammatory genes (including CXCL1, DUOXA2, IL1β, IL8, and IL23α; all P<0.001) and pathways in all conditions. Organoids of non-IBD controls clustered separate from organoids of UC patients. However, Arnauts added that organoids from inflamed and non-inflamed regions in UC patients were indistinguishable, also after inflammatory stimulation. She concluded: “To study UC in an ex vivo model, inflammation should be re-introduced prior to evaluation of other mechanisms. It is, however, not essential for organoid cultures to be obtained from biopsies from inflamed regions in UC patients.”
- Arnauts K, et al. ECCO-IBD 2020, OP11.
Posted on
Previous Article
« Role of immune cells in intestinal fibrosis Next Article
PICaSSO validated in real-life study »
« Role of immune cells in intestinal fibrosis Next Article
PICaSSO validated in real-life study »
Table of Contents: ECCO 2020
Featured articles
Gut Microbiome as Treatment Target
Response to faecal microbiota transplantation in UC
Bioactives produced by gut bacteria to modulate immune response
Big Data Analysis
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Experimental Therapies: Study Results
AMT-101: an oral human IL-10 fusion protein
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Short- and Long-Term Treatment Results
Infliximab discontinuation increases relapse risk
Tofacitinib ‘real-world’ effectiveness in active UC
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Specific Therapeutic Strategies
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
High versus standard adalimumab in active UC
Head-to-Head Comparison of Treatments
Vedolizumab and anti-TNF therapies: a real-world comparison
Cancer Risk
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Miscellaneous Topics
Resolution of mucosal inflammation has dramatic effect
PICaSSO validated in real-life study
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
Related Articles
April 14, 2020
Glyco-fingerprint as risk factor of UC-associated cancer
April 14, 2020
Phase 2 results of first-in-class TL1A inhibitor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com